Andere talen Jacobio Pharmaceuticals Group Co., Ltd.

Aandelen

1167

KYG4987A1094

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:22 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,86 ^HKD	-7,46%		-5,10%	-48,62%

10/05	Jacobio Pharmaceuticals Group Co. Ontvangt goedkeuring voor registratie van fase III klinische studie van Glecirasib (Jab-21822) en Epidermal Growth Factor Receptor Inhibitor Erbitux bij patiënten met colorectale kanker	CI
07/05	Jacobio Pharmaceuticals dient een aanvraag voor een nieuw geneesmiddel voor kankerbehandeling in bij Chinese toezichthouder; aandelen stijgen met 22%	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	10/05
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%	07/05
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint	01/05
Jacobio Pharmaceuticals Plans Auditor Change	25/04
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention	09/04
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting	09/04
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses	01/04
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16%	01/03
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300	01/03
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress	19/02
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13%	19/02
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor	18/02
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7%	22/01
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI	19/01
Jacobio to Present Clinical Results of Pancreatic Cancer Drug in US Meet; Shares Jump 3%	07/12
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium	07/12
Jacobio Presents Clinical Data on Anti-Tumor Drug at Oncology Congress	24-10-23
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo	22-10-23
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Jacobio Pharmaceuticals Group Co., Ltd.

Aandelen

1167

KYG4987A1094

Andere talen

Filters